RxDoctor Payments Data

Andrew Calman, MD

Retina Specialist · San Francisco, CANPI 1447322169

Payments from drug & device makers

$13,448in general payments, 2019–2025

Across 67 payments — averaging $200.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$11K
  • Johnson & Johnson Surgical Vision, Inc.$1K
  • Biotissue Holdings Inc.$315
  • AbbVie$311
  • Alcon$242
  • Novartis$197
  • plus $712 from 14 others
$14,886in research payments, 2019–2025

Across 5 payments — averaging $2977.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Carl Zeiss Meditec, Inc.$15K

What the payments were for

  • Consulting fees$10,63779%
  • Travel & lodging$7205%
  • Food & beverage$2,09216%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,448 in reported general payments places this provider in the 65th percentile of 187 retina specialist providers in California.

See all retina specialist providers in California

Medicare billing

Part B allowed, 2024
$490,814
Medicare patients
624
Services billed
4,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost121$67,740
RestasisCyclosporine19$21,685
XiidraLifitegrast16$17,108
Cyclosporine25$13,779
RocklatanNetarsudil Mesylat/Latanoprost15$9,123
CombiganBrimonidine Tartrate/Timolol15$8,599
SimbrinzaBrinzolamide/Brimonidine Tart26$6,465
Travoprost33$6,376
RhopressaNetarsudil Mesylate14$4,402
Brimonidine Tartrate64$3,895
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$3,593
Prednisolone Acetate117$3,562
Gatifloxacin74$3,381
Latanoprost345$3,179
Bimatoprost23$2,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$311$98,025155 claims
Bausch & Lomb Americas Inc.Xiidra$111$17,10816 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$67$13,52529 claims
AlconSimbrinza$242$6,46526 claims
NovartisTravatan Z$197$1,43911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 187 retina specialist providers in California.

Other retina specialist in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →